Literature DB >> 26348951

Availability and payer coverage of BRCA1/2 tests and gene panels.

Elizabeth Clain1, Julia R Trosman2,3, Michael P Douglas3, Christine B Weldon2,3, Kathryn A Phillips3,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26348951      PMCID： PMC4625918          DOI： 10.1038/nbt.3322

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  12 in total

Review 1.  Genetic predisposition to breast cancer: past, present, and future.

Authors:  Clare Turnbull; Nazneen Rahman
Journal:  Annu Rev Genomics Hum Genet       Date:  2008       Impact factor: 8.929

2.  Myriad decision aftershocks ripple through biotech.

Authors:  Mark Ratner
Journal:  Nat Biotechnol       Date:  2013-08       Impact factor: 54.908

3.  Health technology assessment and private payers' coverage of personalized medicine.

Authors:  Julia R Trosman; Stephanie L Van Bebber; Kathryn A Phillips
Journal:  J Oncol Pract       Date:  2011-05       Impact factor: 3.840

4.  Multiplex genetic testing for cancer susceptibility: out on the high wire without a net?

Authors:  Susan M Domchek; Angela Bradbury; Judy E Garber; Kenneth Offit; Mark E Robson
Journal:  J Clin Oncol       Date:  2013-03-04       Impact factor: 44.544

5.  Development of the clinical next-generation sequencing industry in a shifting policy climate.

Authors:  Margaret A Curnutte; Karen L Frumovitz; Juli M Bollinger; Amy L McGuire; David J Kaufman
Journal:  Nat Biotechnol       Date:  2014-10       Impact factor: 54.908

6.  Two decades after BRCA: setting paradigms in personalized cancer care and prevention.

Authors:  Fergus J Couch; Katherine L Nathanson; Kenneth Offit
Journal:  Science       Date:  2014-03-28       Impact factor: 47.728

Review 7.  Next-generation sequencing for hereditary breast and gynecologic cancer risk assessment.

Authors:  Allison W Kurian; Kerry E Kingham; James M Ford
Journal:  Curr Opin Obstet Gynecol       Date:  2015-02       Impact factor: 1.927

8.  Cancer risk assessment using genetic panel testing: considerations for clinical application.

Authors:  Susan Hiraki; Erica S Rinella; Freya Schnabel; Ruth Oratz; Harry Ostrer
Journal:  J Genet Couns       Date:  2014-03-07       Impact factor: 2.537

9.  Barriers to the use of personalized medicine in breast cancer.

Authors:  Christine B Weldon; Julia R Trosman; William J Gradishar; Al B Benson; Julian C Schink
Journal:  J Oncol Pract       Date:  2012-05-22       Impact factor: 3.840

10.  Eligibility criteria in private and public coverage policies for BRCA genetic testing and genetic counseling.

Authors:  Grace Wang; Mary S Beattie; Ninez A Ponce; Kathryn A Phillips
Journal:  Genet Med       Date:  2011-12       Impact factor: 8.822
View more
  14 in total

1.  Is the ``$1000 Genome'' really $1000? Understanding the full benefits and costs of genomic sequencing.

Authors:  Kathryn A Phillips; Mark J Pletcher; Uri Ladabaum
Journal:  Technol Health Care       Date:  2015       Impact factor: 1.285

2.  Payer Coverage for Hereditary Cancer Panels: Barriers, Opportunities, and Implications for the Precision Medicine Initiative.

Authors:  Julia R Trosman; Christine B Weldon; Michael P Douglas; Allison W Kurian; R Kate Kelley; Patricia A Deverka; Kathryn A Phillips
Journal:  J Natl Compr Canc Netw       Date:  2017-02-10       Impact factor: 11.908

3.  Decision Making on Medical Innovations in a Changing Health Care Environment: Insights from Accountable Care Organizations and Payers on Personalized Medicine and Other Technologies.

Authors:  Julia R Trosman; Christine B Weldon; Michael P Douglas; Patricia A Deverka; John B Watkins; Kathryn A Phillips
Journal:  Value Health       Date:  2017-01       Impact factor: 5.725

4.  Payer coverage policies for multigene tests.

Authors:  Kathryn A Phillips; Patricia A Deverka; Julia R Trosman; Michael P Douglas; James D Chambers; Christine B Weldon; Andrew P Dervan
Journal:  Nat Biotechnol       Date:  2017-07-12       Impact factor: 54.908

5.  Insights From a Temporal Assessment of Increases in US Private Payer Coverage of Tumor Sequencing From 2015 to 2019.

Authors:  Julia R Trosman; Michael P Douglas; Su-Ying Liang; Christine B Weldon; Allison W Kurian; Robin K Kelley; Kathryn A Phillips
Journal:  Value Health       Date:  2020-03-19       Impact factor: 5.725

6.  Patient and genetic counselor perceptions of in-person versus telephone genetic counseling for hereditary breast/ovarian cancer.

Authors:  Aryana S Jacobs; Marc D Schwartz; Heiddis Valdimarsdottir; Rachel H Nusbaum; Gillian W Hooker; Tiffani A DeMarco; Jessica E Heinzmann; Wendy McKinnon; Shelley R McCormick; Claire Davis; Andrea D Forman; Alexandra Perez Lebensohn; Emily Dalton; Diana Moglia Tully; Kristi D Graves; Morgan Similuk; Scott Kelly; Beth N Peshkin
Journal:  Fam Cancer       Date:  2016-10       Impact factor: 2.375

7.  EXAMINING EVIDENCE IN U.S. PAYER COVERAGE POLICIES FOR MULTI-GENE PANELS AND SEQUENCING TESTS.

Authors:  James D Chambers; Cayla J Saret; Jordan E Anderson; Patricia A Deverka; Michael P Douglas; Kathryn A Phillips
Journal:  Int J Technol Assess Health Care       Date:  2017-10-25       Impact factor: 2.188

Review 8.  The role of genomics in global cancer prevention.

Authors:  Ophira Ginsburg; Paul Brennan; Patricia Ashton-Prolla; Anna Cantor; Daniela Mariosa
Journal:  Nat Rev Clin Oncol       Date:  2020-09-24       Impact factor: 66.675

9.  The Global Market for Next-Generation Sequencing Tests Continues Its Torrid Pace.

Authors:  Kathryn A Phillips; Michael P Douglas
Journal:  J Precis Med       Date:  2018-10

10.  Genetic Testing in a Population-Based Sample of Breast and Ovarian Cancer Survivors from the REACH Randomized Trial: Cost Barriers and Moderators of Counseling Mode.

Authors:  Laurie E Steffen; Ruofei Du; Amanda Gammon; Jeanne S Mandelblatt; Wendy K Kohlmann; Ji-Hyun Lee; Saundra S Buys; Antoinette M Stroup; Rebecca A Campo; Kristina G Flores; Belinda Vicuña; Marc D Schwartz; Anita Y Kinney
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-09-29       Impact factor: 4.254
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.